Role of Imatinib in treatment of GIST Meta-analysis
George Baskhroon Gebraeel Gabra;
Abstract
Abstract
Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor located in the gastrointestinal (GI) tract. Characteristically, most GISTs (> 95%) are positive for KIT (CD117) protein staining. Imatinib (also known as “Gleevec” or “Glivec”), a tyrosine kinase inhibitor, was called as “magical bullet,” when it revolutionized the treatment of chronic myeloid leukemia (CML) in 2001. Aim of the Work: To evaluate the efficacy and safety of two dose of imatinib treatment for patients with GISTs, a meta-analysis was performed.
Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor located in the gastrointestinal (GI) tract. Characteristically, most GISTs (> 95%) are positive for KIT (CD117) protein staining. Imatinib (also known as “Gleevec” or “Glivec”), a tyrosine kinase inhibitor, was called as “magical bullet,” when it revolutionized the treatment of chronic myeloid leukemia (CML) in 2001. Aim of the Work: To evaluate the efficacy and safety of two dose of imatinib treatment for patients with GISTs, a meta-analysis was performed.
Other data
| Title | Role of Imatinib in treatment of GIST Meta-analysis | Other Titles | تقييم النتائج والمؤشرات في دور ايماتينيب في علاج اورام الجهاز الهضميمراجعة منهجية وتحليل بعدى لما تم نشره | Authors | George Baskhroon Gebraeel Gabra | Issue Date | 2019 |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| CC2248.pdf | 529.88 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.